L048453 |
5,10,15,20-Tetrakis(4-methoxyphenyl)-21H,23H-porph
|
22112-78-3 |
≥ 95% |
Inquiry |
L048455 |
5,10,15,20-Tetrakis(pentafluorophenyl)porphyrin
|
25440-14-6 |
≥ 95% |
Inquiry |
L048428 |
5,6-Dimethyl-1,10-phenanthroline
|
3002-81-1 |
≥ 95% |
Inquiry |
L048299 |
5-Bromo-2-phenylpyridine
|
27012-25-5 |
≥ 95% |
Inquiry |
L048083 |
5-Methyl-1,10-phenanthroline
|
3002-78-6 |
≥ 95% |
Inquiry |
L047863 |
5-Bromo-1,10-phenanthroline
|
40000-20-2 |
≥ 95% |
Inquiry |
L047810 |
6,6'-Dimethyl-2,2'-bipyridine
|
4411-80-7 |
≥ 95% |
Inquiry |
L045717 |
N,N,2,2-Tetramethyl-1,3-propanediamine
|
53369-71-4 |
≥ 95% |
Inquiry |
L045593 |
2,2'-Bipyridine-4,4'-dicarboxylic acid
|
6813-38-3 |
≥ 95% |
Inquiry |
L045559 |
N-Isopropyl-1,3-propanediamine
|
3360-16-5 |
≥ 95% |
Inquiry |
L045180 |
Tetramethylammonium hydrogen sulfate
|
80526-82-5 |
≥ 95% |
Inquiry |
L040123 |
Tetra(3,5-dibromo-4-hydroxyphenyl)porphyrin
|
125299-79-8 |
≥ 95% |
Inquiry |
L039830 |
2,6-Bis(benzo[d]oxazol-2-yl)pyridine
|
33858-36-5 |
≥ 95% |
Inquiry |
L039831 |
1,3-Bis(benzo[d]oxazol-2-yl)benzene
|
59049-84-2 |
≥ 95% |
Inquiry |
L038012 |
1,4,7-Tritosyl-1,4,7-triazonane
|
52667-89-7 |
≥ 95% |
Inquiry |
L036786 |
N,N'-Bis(3,5-di-tert-butylsalicylidene)-1,1,2,2-te
|
351498-10-7 |
≥ 95% |
Inquiry |
L036564 |
5,10,15,20-Tetrakis(4-aminophenyl)-21H,23H-porphin
|
22112-84-1 |
≥ 95% |
Inquiry |
L036548 |
5,10,15,20-Tetrakis(3,5-dimethoxyphenyl)porphyrin
|
74684-34-7 |
≥ 95% |
Inquiry |
L036549 |
5,15-Di(4-Pyridyl)-10,20-diphenylporphyrin
|
71410-72-5 |
≥ 95% |
Inquiry |
L036552 |
5,10,15,20-Tetrakis(4-fluorophenyl)-21H,23H-porphi
|
37095-43-5 |
≥ 95% |
Inquiry |
L036554 |
5,10,15,20-Tetrakis(4-nitrophenyl)porphyrin
|
22843-73-8 |
≥ 95% |
Inquiry |
L036327 |
Protoporphyrin IX dimethyl ester
|
5522-66-7 |
≥ 95% |
Inquiry |
L035826 |
4,7-Bis(4-bromophenyl)-1,10-phenanthroline
|
97802-08-9 |
≥ 95% |
Inquiry |
L035828 |
4'-(4-Bromophenyl)-2,2':6',2''-terpyridine
|
89972-76-9 |
≥ 95% |
Inquiry |
L035075 |
[2,2'-Bipyridine]-6-carboximidamide hydrochloride
|
219745-75-2 |
≥ 95% |
Inquiry |